X

Trial Profile

A Randomized, Double-Blind, Placebo Controlled Trial of Aldafermin (NGM282) for Treatment of Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldafermin (Primary)
Indications Irritable bowel syndrome
Focus Therapeutic Use

Most Recent Events

08 May 2023 According to NGM Biopharmaceuticals Media Release, manuscript on the study has been accepted and published online in Gastroenterology
08 May 2023 According to NGM Biopharmaceuticals Media Release, data from this study were presented at Digestive Disease Week 2023
08 May 2023 Results published in the NGM Biopharmaceuticals Media Release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com